Drugs / QN-023a
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05665075 | Dec 2022 → Dec 2023 | acute myeloid leukemia | Zhejiang University | Unknown | No outcome recorded |
| Phase 1 | NCT05601466 | Mar 2022 → Apr 2023 | acute myeloid leukemia | Institute of Hematology & Blood Diseases Hospital, China | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QN-023a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05601466 ↗ |
| Modality | Cell therapy | “allogeneic CAR-NK cells targeting CD33” NCT05601466 ↗ |
| Target | CD33 | “targeting CD33” NCT05601466 ↗ |